Effectiveness of bDMARDs in ankylosing spondylitis patients by biologic use: experience from the CorEvitas PsA/SpA Registry.

Philip J MeaseTaylor BlachleyWilliam N MalatestinicLeslie R HarroldBlessing DubeJeffrey R LisseRebecca J BolceTheresa Hunter Gibble

Published in: Current medical research and opinion (2023)

Although AS patients initiate bDMARDs, many do not achieve optimal treatment responses. Future research is needed to investigate the aspects associated with inadequate improvement and treatment response to bDMARDs.

Keyphrases

end stage renal disease
ankylosing spondylitis
chronic kidney disease
newly diagnosed
ejection fraction
rheumatoid arthritis
prostate cancer
peritoneal dialysis
randomized controlled trial
prognostic factors
patient reported outcomes
systemic lupus erythematosus
combination therapy
disease activity